There are currently 80 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Autism participants are Florida, California, Ontario and Texas.
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +580 locations
Conditions: Atrial Fibrillation
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: University of Alabama Hospital, Birmingham, Alabama +155 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Ondansetron for the Management of Atrial Fibrillation
Recruiting
"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/18/2024
Locations: Indiana Clinical Research Center, Indianapolis, Indiana +2 locations
Conditions: Atrial Fibrillation
HEAL-LAA Clinical Trial
Recruiting
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of Alabama Medical Center, Birmingham, Alabama +46 locations
Conditions: Atrial Fibrillation, Bleeding, Stroke
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
All
Ages:
Between 22 years and 85 years
Trial Updated:
03/12/2024
Locations: University of Southern California - Keck School of Medicine, Los Angeles, California +75 locations
Conditions: Atrial Fibrillation
Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF
Recruiting
This prospective randomized study will assess the safety and efficacy of FIRM-guided ablation (FIRM+PVI) compared to pulmonary vein isolation (PVI) without FIRM, for the treatment of symptomatic atrial fibrillation.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/12/2024
Locations: Veterans Affairs Medical Center, San Diego, California +1 locations
Conditions: Atrial Fibrillation
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
Recruiting
Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities for early AF detection and subsequent stroke prevention in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long term arrhythmia information via remote monitoring. The ASSERT-AF study seeks to accurately define the burden of AF and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Heart Failure
High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation
Recruiting
Patients undergoing FIRM guided ablation of atrial fibrillation will undergo high resolution MRI imaging to determine correlation of underlying anatomic fibrotic regions with FIRM targeted sites for ablation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Ohio State University, Columbus, Ohio
Conditions: Atrial Fibrillation
Synaptic Plasticity in the Epicardial Ganglionated Plexi
Recruiting
Atrial fibrillation (AF) is the most common arrhythmia and the prevalence increase with age. Autonomic nervous system play a critical role in the initiation and maintenance of AF. The intrinsic cardiac autonomic nervous system includes ganglionated plexus (GP) modulate the level of parasympathetic activity to the heart. Experimental and clinical studies suggest that GP activation plays a significant role in clinical AF in both the initiation of and the maintenance of AF. Synaptic plasticity is... Read More
Gender:
All
Ages:
Between 21 years and 90 years
Trial Updated:
03/04/2024
Locations: OU Medical Center, Oklahoma City, Oklahoma
Conditions: Atrial Fibrillation
The Vanderbilt Atrial Fibrillation Ablation Registry
Recruiting
The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for transl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/02/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Atrial Fibrillation
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
Recruiting
This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators treat atrial fibrillation. The study will enroll 225 participants. Eligible participants will have undergone sequencing for arrhythmia and cardiomyopathy (CM) genes. Based on those results, participants will be recruited for an outpatient research visit with testing that includes cardiac MRI, rest/stre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/02/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Atrial Fibrillation
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Recruiting
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and De Novo or Redo procedures. Phenotype patients and demonstrate the prognostication power of Electrographic Flow (EGF®) maps among all subjects using 12-month follow-up outcomes following EGF-guided mapping and ablation.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2024
Locations: Banner Health, Phoenix, Arizona +19 locations
Conditions: Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia, Arrhythmias, Cardiac, Atrial Flutter, Atrial Fibrillation, Paroxysmal or Persistent, Atrial Arrhythmia, Atrial Tachycardia